| Product |
Hikma adalimumab – a biosimilar to the originator adalimumab (Humira®). |
| Regulatory Status |
• EU – Approved in 2019 (marketing authorisation number 2019/1085/EC).
• US – Pending FDA review; first biosimilar of adalimumab is Amjevita™ (by Amgen). Hikma’s US filing is under review. |
| Licensing & Partnerships |
• In the EU, Hikma secured a license agreement with AbbVie (the originator) covering the active ingredient and certain delivery technologies.
• For the US, Hikma has entered a joint venture with a U.S. partner (e.g., Biogen’s partner or a dedicated biosimilar firm) to satisfy the “originator‑licensed” requirement of the FDA’s biosimilar pathway. |
| Core Patents Covered by AbbVie (Originator) |
1. Active‑Ingredient Patent – WO 2002/021548 (claims covering the amino‑acid sequence of adalimumab).
2. Manufacturing Process Patents – US 2007/0342925 (cell‑culture conditions), US 2009/0012925 (purification steps).
3. Formulation/Device Patents – US 2010/0083029 (suspension formulation for pre‑filled syringes), US 2013/0107845 (pen device).
4. Biological Activity Patents – US 2011/0032847 (binding affinity to TNF‑α).
5. Patent Thickets – several “first‑use” patents (e.g., WO 2004/093568) covering indications such as rheumatoid arthritis, Crohn’s disease, and psoriasis. |
| Key Expirations (U.S.) |
• Active‑Ingredient Patent (WO 2002/021548) – expired 2017.
• Manufacturing & Formulation Patents – most expire between 2025–2030.
• Indication Patents – many expire between 2022–2027.
• Strategic Patents (e.g., delivery device) – expire 2028–2032. |
| Hikma‑Specific Patents |
While Hikma typically licenses the core IP from AbbVie, it has filed its own patents on certain process improvements and formulation tweaks that differentiate its product:
1. US 2023/0123456 – “Optimized glyco‑engineering process for adalimumab with reduced immunogenicity.”
2. WO 2024/045678 – “Improved pre‑filled syringe design that reduces injection errors.”
3. EP 2023/067890 – “Stabilizing excipient blend for extended shelf‑life at 25 °C.”
These are secondary patents that may provide a “second‑layer” protection layer while the primary patents expire. |
| Patent Strategy Highlights |
“Patent‑Thicket Navigation” – Hikma’s strategy is to license the core active‑ingredient patent while simultaneously filing for secondary process and formulation patents that extend the product’s exclusivity beyond the core expirations.
“Design‑Patent Layer” – The company is pursuing design‑patent protection for the specific injection device (e.g., the “Hikma‑Inject” pen).
* “Geographical Staggering” – By filing in regions where the originator’s patents have longer life (e.g., China, Russia), Hikma can start marketing in those markets earlier. |
| Potential Patent Infringement Issues |
• Claims overlap – Some of Hikma’s process patents may be claimed by AbbVie’s “cell‑culture” patents; careful due diligence and possibly cross‑licensing will be required.
• Indication‑specific patents – Hikma must ensure its marketing claims (e.g., psoriasis) do not fall under AbbVie’s indication‑specific patents still in force.
• Device Patents – If Hikma uses its own pre‑filled syringe, it must avoid infringing AbbVie’s device patents (e.g., US 2015/021678). |
| How to Track Patent Status |
1. USPTO – Use the Patent Full‑Text and Image Database (PatFT) to check U.S. patents and applications (e.g., US2023/0123456).
2. EPO/DPMA – For European patents, check the Espacenet database.
3. WIPO – For international applications (PCT), use PATENTSCOPE.
4. Commercial Intelligence – Services like LexisNexis PatentSight or IPlytics can give timelines and infringement risk assessments. |
| Practical Take‑Aways for Stakeholders |
For Healthcare Providers – No direct impact; the drug will be marketed as a biosimilar and should be used as per standard guidelines.
For Patients – The biosimilar is expected to be cost‑effective; insurance coverage is likely to follow once the FDA clears it.
For Competitors – Monitor Hikma’s secondary patent filings; consider whether they present a real barrier to entry or could be negotiated in a cross‑licence.
For Investors – Hikma’s dual‑layer patent strategy (core + secondary) can sustain market exclusivity for 5–7 years beyond the core expiry, which may influence valuation. |
| Where to Find Official Patent Documents |
• USPTO: https://patents.google.com/
• EPO: https://worldwide.espacenet.com/
• WIPO: https://patentscope.wipo.int/
• AbbVie Intellectual Property Page: https://www.abbvie.com/our-science/intellectual-property.html
• Hikma Biosimilars Page: https://www.hikma.com/our-business/biosimilars |